Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results

-- LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158$169.1 million, in line with preliminary results published January 8 -- Reiterates 2025 guidance, with the number of patients on LUMRYZ expected to increase to 3,300-3,500 by year-end, generating $240-$260 million in net product revenue and cash flow of $20-40 million -- Executing multiple initiatives to accelerate patient demand for LUMRYZ -- Patient enrollment is on track in the Phase ...